Showing 123 results
-
Media Release /Makati City, 21 May 2024 – Novartis Healthcare Philippines inaugurated its new office with a workspace that is designed to foster collaboration, innovation and sustainability. The new Novartis…
-
Media Release /High levels of low-density lipoprotein cholesterol (LDL-C or bad cholesterol) can lead to an accumulation of fatty plaques in the arteries that supply blood to the heart, lungs, and brain. Clogging…
-
Media Release /The first-ever Think Pink Awards on Outstanding Stories on Breast Cancer was co-organized by the Philippine Press Institute (PPI) in partnership with Novartis and the ICanServe Foundation, coinciding…
-
Media Release /Novartis Healthcare Philippines and AC Health have launched their Integrated Cardiovascular and Cancer Care partnership that aims to broaden access to innovative medicines for breast cancer, heart…
-
Media Release /Photo shows (from left): Ms. Christine Fajardo, Communications & Engagement Head, Novartis Healthcare Philippines; Dr. Alfonso Nuñez III, Chief, East Avenue…
-
Media Release /Patient navigators took center stage at the plenary session supported by Novartis Healthcare Philippines during the Philippine National Cancer Summit 2024. Entitled “Beyond the Pink Ribbon:…
-
Media Release /The 4th annual Alliance & Partnerships for Patient Innovation & Solutions (APPIS) Summit will take place on Tuesday, March 19, and Wednesday, March 20, 2024.Co-created by the APPIS 2024…
-
Media Release /In line with its mission of extending and improving the lives of those with breast cancer, Novartis is supporting the 5th Philippine National Cancer Summit (PNCS) scheduled on 29 February to 01 March…
-
Media Release /In support of the Universal Health Care (UHC) Act and to enhance the patient journey in the country, Novartis Healthcare Philippines has partnered with the Rizal Medical Center (RMC) to launch STAHR…
-
Media Release /The Philippine Food and Drug Administration (FDA) has approved inclisiran for the treatment of hypercholesterolemia or mixed dyslipidemia.Inclisiran is a first-in-class small interfering RNA (siRNA)…
